The protective effects of cabozantinib against high glucose-induced damages in in vitro renal glomerular endothelial cells model via inhibition of early growth response-1 (Egr-1)

Cabozantinib is a tyrosine kinase inhibitor with anti-tumor activity in kidney cancer. However, the efficacy of cabozantinib in other renal diseases has never been reported. Here, we focused on exploring the effect of cabozantinib on diabetic nephropathy (DN). The biofunctions of cabozantinib in hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Hanlu, Yan, Jingjing, Wang, Qiong, Tian, Hui, Zhou, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161968/
https://www.ncbi.nlm.nih.gov/pubmed/35441585
http://dx.doi.org/10.1080/21655979.2022.2063667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161968/
https://www.ncbi.nlm.nih.gov/pubmed/35441585
http://dx.doi.org/10.1080/21655979.2022.2063667

Ejemplares similares